Back to Search
Start Over
Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma
- Source :
- Urologic oncology. 33(6)
- Publication Year :
- 2015
-
Abstract
- To assess the efficacy and tolerability of sunitinib dosing schedule of 2 weeks on and 1 week off (schedule 2/1) vs. the traditional schedule of 4 weeks on and 2 week off (schedule 4/2) and its influence on health-related quality of life (HRQoL) in Chinese patients with metastatic renal cell carcinoma (mRCC).A retrospective analysis of 108 patients with mRCC who were treated with sunitinib regimens (50mg daily) between January 2009 and July 2013 was undertaken. Overall, 3 groups of patients were studied according to the dosing schedule they received: schedule 4/2 (n = 50), transitional schedule 2/1 (T2/1; patients switched from schedule 4/2 to 2/1; n = 26), and initial schedule 2/1 (I2/1; n = 32). The tumor response, progression-free survival (PFS) time, adverse events, and HRQoL were assessed and compared among the groups.The incidences of diarrhea, fatigue, hand-foot syndrome, and neutropenia induced by the treatment of sunitinib were all significantly less common with schedule I2/1 and T2/1 than with schedule 4/2 (P0.05). Although there was no statistically significant difference in the tumor response among the 3 groups, the median PFS time was significantly longer with schedule I2/1 than with schedules T2/1 and 4/2 (11.2 vs. 9.4 and 9.5mo, respectively, P = 0.030), and HRQoL (as determined by 19-item Functional Assessment of Cancer Therapy Kidney Symptom Index scores) was better.Treatment with sunitinib 50mg daily using a 2/1 dosing schedule can provide better tolerability and a longer PFS with better HRQoL in Chinese patients with mRCC than the traditional schedule 4/2.
- Subjects :
- Oncology
Adult
Male
medicine.medical_specialty
Schedule
Indoles
Urology
Neutropenia
urologic and male genital diseases
Drug Administration Schedule
Quality of life
Asian People
Renal cell carcinoma
Internal medicine
medicine
Sunitinib
Humans
Pyrroles
Dosing
Neoplasm Metastasis
Adverse effect
Carcinoma, Renal Cell
Aged
Aged, 80 and over
business.industry
Middle Aged
medicine.disease
Treatment Outcome
Tolerability
Quality of Life
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 18732496
- Volume :
- 33
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Urologic oncology
- Accession number :
- edsair.doi.dedup.....9ada2902617c41a339b17513a2193109